ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meeting Abstracts
    • All Meetings
    • PRSYM 2026
    • ACR Convergence 2025
    • Download Abstract Supplements
  • Keyword Index
  • Search
  • My Favorites
    • View and print all favorites
    • Clear all favorites

Abstract Number: 1363

Changes in Cyclooxygenase-2’s Expression, and PGE2’s and 6-Keto-PGF1α Levels in the Presence of the Muscarinic Acethylcholine Receptor Antibody in Primary Sjogren Syndrome

Micaela Ana Cosatti1, Silvia Reina2, Cecilia N. Pisoni3, Alicia Eimon4, Sabrina Ganzinelli2 and Enri Borda2, 1Section Rheumatology and Immunology, CEMIC, CABA, Argentina, 2Pharmacology Unit, School of Dentistry, University of Buenos Aires, Buenos Aires, Argentina; National Research Council of Argentina (CONICET), Buenos Aires, Argentina, 3Lupus Research Unit, The Rayne Institute, St Thomas' Hospital and Kings College London, London, United Kingdom, 4CEMIC, Buenos Aires, Argentina

Meeting: ACR/ARHP Annual Meeting 2015

Date of first publication: September 29, 2015

Keywords: autoantibodies, cyclooxygenase and prostaglandins, Sjogren's syndrome

  • Tweet
  • Email a link to a friend (Opens in new window) Email
  • Print (Opens in new window) Print
Session Information

Date: Monday, November 9, 2015

Title: Innate Immunity and Rheumatic Disease Poster II

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: to assess the inflammatory process provoked by the M3 muscarinic acetylcholine receptor antibody from primary Sjogren Syndrome (pSS) patient’s sera in rat submandibular gland by measuring the expression of mRNA COX-2 and production of PGE2 and PGI2.

Methods:

The levels and the generation of PGE2, 6-keto-PGF1α by Enzyme-linked immunoabsorbent assay (ELISA), cyclic AMP (cAMP) by cAMPc-RIA kit and COX-2 mRNA gene’s expression at Real Time PCR in rat submandibular gland acini’s preparations were measured in the presence of the autoantibodies alone or after incubation with different inhibitors. PGE2 and 6-keto-PGF1α were also measured in serum from pSS patients.

Statistical analyses

The Student’s “t” test for unpaired values was used to determine the level of significance. Differences between means were considered significant if P<0.05.

Results:

To determine the effect of pSS IgG anti M3 peptide on gland acini’s we analyzed the time-course of COX-2 mRNA expression by Real Time-PCR. COX-2-mRNA was significantly (P<0.001) increased in the presence of pSS IgG anti M3 versus normal serum (control). When the autoantibody was incubated in the presence of DuP697 (1×10-6 M) [a specific COX-2 antagonist] under the same experimental conditions, it abrogated the increment of COX-mRNA’s expression in a significant manner (P<0.01).

Primary Sjogren Syndrome IgG anti M3 antibody increased the production of both prostanoids PGE2 and 6-keto-PGF1α on submandibular gland acini’s in a dose-response concentration curve reaching the maximal when the antibody concentration is 1×10-8 M. The increment in the generation of both prostanoids is abrogated, reaching values similar to basal ones, when the tissue preparations are incubated with prostanoid antagonists PF-04418948 2×10-9 M  and RO3244794 5×10-8 M  for PGE2 and 6-keto-PGF1α respectively, and in the presence of synthetic M3 peptide 5×10-6 M.

To ascertain if cAMP increment is caused by the generation of PGE2 and 6-keto-PGF1α in our preparation, we studied the action of both prostanoids on the production of this nucleotide. Both prostaglandins were able to increase cAMP production, whereas the selective prostanoids antagonists   (PF-04418948 for PGE2 and RO3244794 for 6-keto-PGF1α) blunted the stimulatory action provoked by the prostaglandins.

The levels of PGE2 and 6-keto-PGF1α were studied in serum of 28 pSS patients and in 25 healthy individuals.  The concentration of 6-keto-PGF1α and PGE2 in serum of pSS patients was two standard deviations higher than that in normal individuals (P<0.001).

Conclusion: The present study suggests a complex interplay between different factors involved in adaptativa autoimmunity in pSS patients at the level of exocrine glands. The presence of anti M3 IgG autoantibody from pSS sera was able to stimulate COX-2 mRNA gene’s expression and the increment in the generation of PGE2 and 6-keto-PGF1α abolished by M3 specific cholinergic antagonist. The prostanoids play an important role in the inflammatory process at exocrine gland level.


Disclosure: M. A. Cosatti, None; S. Reina, None; C. N. Pisoni, None; A. Eimon, None; S. Ganzinelli, None; E. Borda, None.

To cite this abstract in AMA style:

Cosatti MA, Reina S, Pisoni CN, Eimon A, Ganzinelli S, Borda E. Changes in Cyclooxygenase-2’s Expression, and PGE2’s and 6-Keto-PGF1α Levels in the Presence of the Muscarinic Acethylcholine Receptor Antibody in Primary Sjogren Syndrome [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/changes-in-cyclooxygenase-2s-expression-and-pge2s-and-6-keto-pgf1-levels-in-the-presence-of-the-muscarinic-acethylcholine-receptor-antibody-in-primary-sjogren-syndrome/. Accessed .
  • Tweet
  • Email a link to a friend (Opens in new window) Email
  • Print (Opens in new window) Print

« Back to ACR/ARHP Annual Meeting 2015

ACR Meeting Abstracts - https://acrabstracts.org/abstract/changes-in-cyclooxygenase-2s-expression-and-pge2s-and-6-keto-pgf1-levels-in-the-presence-of-the-muscarinic-acethylcholine-receptor-antibody-in-primary-sjogren-syndrome/

Advanced Search

My Favorites

Save and print abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract (must have cookies enabled in browser). See saved favorites.

Abstract Policies

  • ACR Convergence Abstract Embargo Policies
  • ACR Convergence Abstract Permissions & Reprints
  • PRSYM Abstract Policies

ACR Convergence. Where Rheumatology Meets

ACR Convergence 2026

Join us November 6-11 in Orlando, Florida.
See Registration Information

  • Contact ACR
  • Privacy Policy
  • ACR Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology